Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Clinical reports documenting the beneficial effects of botulinum toxin (BTX) to treat various lower urinary tract disorders of muscle spasticity (e.g. detrusor hyperreflexia, detrusor sphincter dyssynergia) have led to its expanded application in non-neurogenic conditions such as idiopathic detrusor overactivity, detrusor underactivity and benign prostatic hyperplasia (BPH). As greater numbers of investigators report their results utilizing this agent, it becomes more important that clinicians are able to synthesize and describe the findings of current clinical studies in a meaningful way. Evidence-based medicine is a platform on which investigations concerning a particular topic can be evaluated for their levels of scientific evidence, so that rational clinical recommendations can be formulated. This review article applies evidence-based practices to the use of BTX in common urologic conditions. Appreciating the benefits as well as limitations of currently available studies will hopefully drive the development of well-controlled, randomized studies of BTX, particularly in highly prevalent conditions such as idiopathic detrusor overactivity and BPH.
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Christopher P
CP
Smith
George T
GT
Somogyi
Timothy B
TB
Boone
D001905:Botulinum Toxins / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D014522:Urethral Diseases / Q000188:drug therapy; D001745:Urinary Bladder Diseases / Q000188:drug therapy; D014570:Urologic Diseases / Q000188:drug therapy*
D001905:Botulinum Toxins